Related Experiment Video
Updated: Apr 29, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Systemic bevacizumab for simultaneous treatment of cancer and choroidal neovascularisation
Norman Saffra1, Benjamin Reinherz2
1Medical and Surgical Eyesite, Brooklyn, New York, USA Department of Ophthalmology, St. Johns Episcopal Hospital, Far Rockaway, New York, USA.
Abstract:
A 47-year-old woman with a medical history of pseudoxanthoma elasticum and associated choroidal neovascularisation that was successfully managed with intravitreal bevacizumab injections developed non-squamous non-small cell lung carcinoma. The patient's oncological medication regimen included systemic bevacizumab. During the 22 months that the patient received systemic bevacizumab for management of her malignancy, intravitreal bevacizumab injections were held and the patient's visual acuity remained stable and the subretinal space was free of fluid leakage.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

